Key facts
- This page summarizes Susan Rodriguez's Form 4 filing for AVADEL PHARMACEUTICALS PLC (AVDL).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Feb 2026, 17:36.
Susan Rodriguez - 12 Feb 2026 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- AVDL
- Reported as of
- 12 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2026, 17:36:43 UTC
- Prior SEC filing
- 03 Jun 2025
- Next SEC filing
- 04 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert E. Puopolo, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Susan Rodriguez filed Form 4 for AVADEL PHARMACEUTICALS PLC (AVDL) on 12 Feb 2026.
Change
- Previous filing in this sequence was filed on 03 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001812511
Primary reporting owner
Rodriguez Susan
- Relationship
- Chief Operating Officer
- Address
- C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND
- Signature
- /s/ Robert E. Puopolo, as Attorney-in-Fact
- Signature date
- 12 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVDL
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -300,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Feb 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 300,000
- Exercise price
- $9.59
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Susan Rodriguez is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.
Footnote F2
(continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of the $21.00 over the applicable exercise price per Ordinary Share under such Option immediately prior to the Effective Time and (ii) a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share subject to such Option immediately prior to the Effective Time (without regard to vesting), contingent upon achievement of certain milestones.